Weekly Investment Analysts’ Ratings Changes for Apellis Pharmaceuticals (APLS)

A number of firms have modified their ratings and price targets on shares of Apellis Pharmaceuticals (NASDAQ: APLS) recently:

  • 7/10/2018 – Apellis Pharmaceuticals is now covered by analysts at Cowen Inc. They set an “outperform” rating and a $40.00 price target on the stock.
  • 7/2/2018 – Apellis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. “
  • 6/27/2018 – Apellis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $52.00 price target on the stock. They wrote, “We reiterate our OW rating and 12-month price target of $52/share on the company’s R&D day hosted on 6/26. Apellis reviewed details for its two Phase 3 programs with APL-2 in geographic atrophy (GA) and paroxysmal nocturnal hemoglobinuria (PNH), presented initial results from its Phase 2 study in autoimmune hemolytic anemia (AIHA), and provided an update on its Phase 2 PNH study. The company also reported early enrollment of the first patient for the Phase 3 PNH trial. Based on the totality of clinical data supporting APL-2 in GA and PNH, we believe the drug is well-positioned to succeed for both indications, which appear to have blockbuster potential.””
  • 6/25/2018 – Apellis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. “
  • 6/18/2018 – Apellis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. “
  • 6/12/2018 – Apellis Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. “
  • 6/7/2018 – Apellis Pharmaceuticals was given a new $52.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 6/6/2018 – Apellis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. “
  • 5/31/2018 – Apellis Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. “
  • 5/23/2018 – Apellis Pharmaceuticals is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating on the stock. They wrote, “We are initiating on Overweight rating and $52 price target. Apellis is in development of APL-2, a C3 complement inhibitor, for the treatment of complement-mediated diseases such as geographic atrophy (GA) and paroxysmal nocturnal hemoglobinuria (PNH), which are both entering Phase 3 development in 2H18. In our view, APL-2 has the potential to offer a first-in-class treatment for GA, a late stage dry form of AMD, and first-line therapy for PNH, an ultra rare orphan blood disorder. In our view, the compelling Phase 2 programs behind APL-2 support a high potential for success for APL-2 to serve these multi- billion market opportunities.””

Apellis Pharmaceuticals traded down $0.50, reaching $18.80, on Thursday, MarketBeat.com reports. 361,700 shares of the company’s stock were exchanged, compared to its average volume of 290,086. The company has a quick ratio of 22.37, a current ratio of 22.37 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $1.13 billion and a PE ratio of -5.12. Apellis Pharmaceuticals Inc has a 52 week low of $12.45 and a 52 week high of $32.00.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Monday, April 30th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.11). analysts anticipate that Apellis Pharmaceuticals Inc will post -1.62 earnings per share for the current fiscal year.

In other news, insider Lukas Scheibler acquired 2,935 shares of the business’s stock in a transaction dated Thursday, May 24th. The stock was bought at an average cost of $20.37 per share, for a total transaction of $59,785.95. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 9.30% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC bought a new position in shares of Apellis Pharmaceuticals in the first quarter valued at approximately $126,000. Wells Fargo & Company MN boosted its position in shares of Apellis Pharmaceuticals by 285.3% in the first quarter. Wells Fargo & Company MN now owns 6,149 shares of the company’s stock valued at $136,000 after acquiring an additional 4,553 shares during the period. American International Group Inc. bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at approximately $158,000. The Manufacturers Life Insurance Company bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at approximately $186,000. Finally, Rhumbline Advisers bought a new position in shares of Apellis Pharmaceuticals in the first quarter valued at approximately $206,000. Institutional investors own 36.72% of the company’s stock.

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Receive News & Ratings for Apellis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply